Market – Page 2

Three-Month Drought in U.S. Biotech IPOs: Recent Developments and Context

2 months ago talkbio0Tagged Droughts, IPO, Market, stocks

biotech IPO; biotech market; IPO drought; 2025; biotech fundraising; biotech stocks

Galapagos Reconsiders Company Split After Market Developments

2 months ago talkbio0Tagged Cell Therapy, Company Split, conditions, Drug Development, Galapagos, Leadership Change, Market, strategic review

Galapagos; company split; cell therapy; drug development; strategic review; leadership change; market conditions

AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil

3 months ago talkbio0Tagged Ambulatory Care Facilities, Aortic Valve Insufficiency, Artificial Intelligence, Biotech Layoffs, biotechnology layoffs, Drug Discovery, Industry, Insitro, Market, Readiness, restructuring, trends qualifier

Insitro, AI drug discovery, biotechnology layoffs, workforce reduction, tumultuous market, industry restructuring, biotech market trends, clinic readiness, cost-cutting, 2025 biotech layoffs

Biotech stocks plunge and industry figures left to wonder after Prasad’s FDA appointment

3 months ago talkbio0Tagged Appointments, Cell Therapy, figures, Industry, Market, Prasad, stocks, United States Food and Drug Administration

United States Food and Drug Administration, Industry, Prasad, Appointments, stocks, Cell Therapy, Market, figures

Capricor shares turn red as FDA plans deramiocel adcomm, likely the first under new commissioner

3 months ago talkbio0Tagged Biologics License Application, Capricor, deramiocel, first, Market, Review [Publication Type], United States Food and Drug Administration

United States Food and Drug Administration, Capricor, deramiocel, Market, Review [Publication Type], Biologics License Application, first

PTC’s Novartis-partnered Huntington’s drug disappoints in mid-stage data reveal

3 months ago talkbio0Tagged factor IX, Huntington 's disease, Market, PTC518

PTC518, factor IX, Huntington ‘s disease, Market

‘Deviated from the core’: Akeso CEO tries to reset expectations of bispecific’s survival readout amid market tumult

3 months ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Keytruda head-to-head trial, Market, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Reaction, summit

Ivonescimab, PD-1xVEGF bispecific antibody, Overall survival (OS) readout, Keytruda head-to-head trial, HARMONi-2 trial, Non-small cell lung cancer (NSCLC), Market reaction, Summit Therapeutics

Mercks Gardasil sales sink further amid China market pressure

3 months ago talkbio0Tagged China, Gardasil, Gardasil sales, Growth, Market, Pressure- physical agent

Market, China, Gardasil, Gardasil sales, Pressure- physical agent, Growth, China

Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations

3 months ago talkbio0Tagged CEOs, EU, Financial cost, Investments, Market, nations, Novartis, Parity, Pharma, Prices, sanofi, Transplant Registry Unified Management Program, U.S.

EU, Novartis, CEOs, Transplant Registry Unified Management Program, Financial cost, Parity, sanofi, Investments, Prices, Pharma, Market, nations, U.S.

Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug

3 months ago talkbio0Tagged Approved, competition, eli lilly, Glucagon-Like Peptide 1, Market, Nordisk, Novo, Obesity, Oral cavity, Pressure- physical agent, semaglutide, United States Food and Drug Administration

Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration